Lorlatinib is a brain-penetrant third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) which covers a broader ALK resistance profile than second-generation ALK TKIs. It has previously demonstrated improved PFS and IC activity compared to crizotinib in treatment-naïve patients with advanced ALK+ NSCLC in the ongoing randomized phase 3 CROWN study.

Osimertinib is a third-generation, orally administered epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) previously approved for the first-line treatment of EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).1,2 Results from the phase 3 FLAURA trial showed that os

Non-small cell lung cancer (NSCLC) accounts for 85%of all types of lung cancer and is the most common cancer in Hong Kong with a total of 5,575 cases in 2019.^1,2 Approximately 30% of NSCLC patients are diagnosed as early stage, and surgical resection is the preferred treatment option for possibly co

The third interim analysis of the GARNET trial confirmed the durable antitumor activity of dostarlimab among patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC) with extended follow-up.1 Based on the positive long-term results, the United States (US) Food and

Despite recent advances in oncology, drug resistance and disease relapse have remained a significant unmet need among non-small cell lung cancer (NSCLC). Recently, the development of novel therapeutics including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have made multiple breakthroughs in the treatment of NSCLC. In a virtual meeting and clinical debate, “Durvalumab in EGFRm Stage III NSCLC – To Offer or Not to Offer?”, Dr. Victor Lee summarized the key studies of NSCLC treatments, including the phase 3 PACIFIC trial of an anti-programmed cell death receptor ligand 1 (PD-L1) drug, durvalumab. Dr. Oscar Chan and Dr. Jonathan Nyaw then discussed the applications and other considerations of the durvalumab regimen among stage 3 Epidermal Growth Factor Receptor mutated (EGFRm) NSCLC patients in the clinical setting.

With advancement in biomarker-driven treatment and targeted therapies for lung cancer, novel strategies are employed to optimize personalized regimens for different subtypes of lung cancer.¹ To keep track of the evolving lung cancer management, a symposium regarding biomarker and treatment landscape for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) was held at the World Conference on Lung Cancer 2021.¹

Immunotherapies targeting the programmed death protein 1 (PD-1)/programmed death-ligand1 (PD-L1) pathway, either administered as a monotherapy or in combination with chemotherapy, have transformed the lung cancer treatment.' While the inclusion of chemotherapy to anti-PD-L1 may provide early disease control, adding anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) to anti- PD-L1 with or without chemotherapy may confer long-term survival benefits for some patients. ¹

POSEIDON is a randomized, open label, multicenter phase 3 study evaluating durvalumab with and without tremelimumab in combination with chemotherapy regimens as first-line treatment for squamous or non-squamous metastatic non-small cell lung cancer (mNSCLC).' The eligible patients with metastatic non-small cell lung cancer (mNSCLC) received a combined regimen of durvalumab, tremelimumab, and chemotherapy. Progression-free survival significantly improved for patients receiving durvalumab plus chemotherapy compared with chemotherapy alone, with a positive trend for overall survival that did not reach statistical significance.'

The field of immunotherapy has been rapidly evolving and is increasingly utilized in the management of lymphomas.¹ Currently, various immunotherapeutic modalities have been pursued including monoclonal antibodies, bispecific T-cell engagers (BiTEs), checkpoint inhibitors and chimeric antigen recepto

Dr. Mariano Provencio, Hospital Universitario Puerta de Hierro, Spain, explained that options to improve poor lung cancer survival include adjuvant treatment for stage I and II and neoadjuvant treatment for stage III disease. Where both neoadjuvant and adjuvant treatments provide a clinically signif